Here’s what you should know.
1. Hepcortespenlisimut-L is a once daily tablet of an oral immunotherapeutic vaccine.
2. Key Capital proved it was safe and highly effective in treating 75 advanced liver cancer patients through a phase II study.
3. More than 90 percent of patients were alive after a 12 month follow-up. A competitor product touts a 10 percent survival rate.
4. After two months, 50 of the 75 patients had their hepatic tumor marker decline, indicating a 66.7 percent response rate.
5. Twelve patients had normal alpha-fetoprotein levels experienced tumor clearance.
6. Researchers observed no adverse events at the time.
7. Key Capital is in the midst of a phase III study at Mongolian National Cancer Center in China.
More articles on gastroenterology:
Inflammatory bowel disease value-based model improves outcomes, lowers costs: 3 study insights
GI leader to know: Dr. Matthew Grossman of Gastroenterology Associates of New Jersey
Water exchange increases adenoma detection rate over alternatives: 5 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.